FHND9041 Versus Afatinib for Non-small Cell Lung Cancer

NCT06759857 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: FHND9041
DRUG: Afatinib

Sponsor

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.